{
    "clinical_study": {
        "@rank": "147875", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1", 
                "arm_group_type": "Experimental", 
                "description": "12 Japanese and 12 Caucasian subjects.  10 out of 12 will receive lomitapide and 2 will receive placebo."
            }, 
            {
                "arm_group_label": "Cohort 2", 
                "arm_group_type": "Experimental", 
                "description": "8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive lomitapide and 2 will receive placebo."
            }, 
            {
                "arm_group_label": "Cohort 3", 
                "arm_group_type": "Experimental", 
                "description": "8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive lomitapide and 2 will receive placebo."
            }, 
            {
                "arm_group_label": "Cohort 4", 
                "arm_group_type": "Experimental", 
                "description": "8 Japanese and 8 Caucasian subjects. 6 out of 8 subjects will receive lomitapide and 2 will receive placebo."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and\n      multiple ascending dose (MAD) study of orally administered lomitapide in healthy male\n      Japanese and Caucasian subjects with elevated LDL-C. The purpose for this study is to\n      evaluate the PK and PD of lomitapide in Japanese subjects as compared to Caucasian subjects."
        }, 
        "brief_title": "Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Subject is a healthy male Caucasian or Japanese, aged 20 - 45 years, inclusive, at\n             screening.\n\n             2. Subject has a BMI of 18.5 - 30 kg/m2 inclusive at screening.\n\n             3. Subjects must have a screening LDL-C measurement and the mean of Day 5 and Day 6\n             measurements greater than or equal to 120mg/dL.\n\n             4. Subjects must agree to use acceptable methods of contraception (details provided\n             in the protocol)\n\n             5. Subjects must be capable of understanding and complying with the requirements of\n             the protocol and must have signed the informed consent form prior to undergoing any\n             study-related procedures.\n\n        Exclusion Criteria:\n\n          1. Subject has a clinically significant disease or any condition or disease that might\n             affect drug absorption, distribution or excretion.\n\n          2. Any clinically significant abnormal laboratory, vital signs or other safety findings\n             as determined by medical history, physical examination or other evaluations conducted\n             at screening or on admission.\n\n          3. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening)\n             which in the opinion of the Investigator is clinically relevant or will interfere\n             with the ECG analysis.\n\n          4. History or current evidence of any clinically relevant cardiovascular, pulmonary,\n             hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic,\n             neurological, psychiatric or other disease.\n\n          5. Positive results in any of the serology tests for Hepatitis B Surface Antigen\n             (HbsAg), anti-Hepatitis core antibody (anti-HBc Ig G [and anti-HBc IgM if IgG is\n             positive], Hepatitis C antibodies (anti-HCV), and HIV 1 and 2 antibodies, (anti-HIV\n             1/2).\n\n          6. Confirmed positive results from urine drug screen or from the alcohol breath test at\n             screening and on admission (Day -1).\n\n          7. History or clinical evidence of alcohol or drug abuse.\n\n          8. Mentally handicapped.\n\n          9. Participation in a drug trial within 90 days prior to first drug administration.\n\n         10. Use of any medication (including over-the-counter (OTC) medication) within 2 weeks\n             prior to admission (Day -1) or within less than 10 times the elimination half-life of\n             the respective drug, or anticipated concomitant medication during the treatment\n             periods.\n\n         11. Use of any substance inhibiting CYP3A4 enzymes within 2 weeks prior to admission (Day\n             -1).\n\n         12. Donation of more than 500 mL of blood within 90 days prior to drug administration.\n\n         13. Subjects who smoke more than 10 cigarettes or equivalent amount of tobacco per day\n             and/or who cannot stop smoking for the duration of the study whilst in the CPU.\n\n         14. Treatment with herbal supplements during the 7 days prior to dosing, or use of\n             vitamins during 48 hours prior to admission (Day -1).\n\n         15. Any circumstances or conditions, which, in the opinion of the PI, may affect full\n             participation in the trial or compliance with the protocol.\n\n         16. Legal incapacity or limited legal capacity at screening.\n\n         17. Subjects who are vegetarians, vegans or have any dietary restrictions conflicting\n             with the study standardised menus.\n\n             -"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01760187", 
            "org_study_id": "AEGR-733-023", 
            "secondary_id": "2012-004220-37"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cohort 1", 
                "Cohort 2", 
                "Cohort 3", 
                "Cohort 4"
            ], 
            "intervention_name": "lomitapide", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Croydon", 
                    "country": "United Kingdom", 
                    "state": "Surrey", 
                    "zip": "CR7 7YE"
                }, 
                "name": "Richmond Pharmacology Ltd"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Lomitapide in Japanese and Caucasian Volunteers With Elevated Low-density-lipoprotein(LDL-C)", 
        "overall_official": {
            "affiliation": "Richmond Pharmacology Limited", 
            "last_name": "Ulrike Lorch, MD FRCA FFPM", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To compare the pharmacokinetics (PK) of lomitapide between Japanese and Caucasian subjects with elevated LDL-C after single and multiple doses, across the dose range studied.", 
            "measure": "Pharmacokinetics (PK) comparison", 
            "safety_issue": "No", 
            "time_frame": "Pharmacokinetic samples will be taken pre-dose on Day 1 up to Day 27 post treatment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01760187"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess the single dose and multiple dose safety of lomitapide in Japanese and Caucasian subjects with elevated LDL-C.", 
                "measure": "To evaluate the number of adverse events and changes in laboratory parameters in order to assess safety of lomitapide in Japanese and Caucasian subjects with elevated LDL-C.", 
                "safety_issue": "Yes", 
                "time_frame": "Samples will be taken pre-dose on Day 1 up to Day 27 post treatment."
            }, 
            {
                "description": "To assess the single dose and multiple dose tolerability of lomitapide in Japanese and Caucasian subjects with elevated LDL-C.", 
                "measure": "To evaluate the number of adverse events and changes in laboratory parameters in order to assess tolerability in Japanese and Caucasian subjects with elevated LDL-C.", 
                "safety_issue": "No", 
                "time_frame": "Samples will be taken pre-dose on Day 1 up to Day 27 post treatment"
            }, 
            {
                "description": "To assess the pharmacodynamic(PD) of lomitapide in Japanese and Caucasian subjects with elevated LDL-C.", 
                "measure": "To evaluate the number of adverse events and changes in laboratory parameters in order to assess pharmacodynamics(PD)of lomitapide in Japanese and Caucasian subjects with elevated LDL-C.", 
                "safety_issue": "No", 
                "time_frame": "Samples will be taken pre-dose on Day 1 up to Day 27 post treatment."
            }
        ], 
        "source": "Aegerion Pharmaceuticals, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Richmond Pharmacology Limited", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Aegerion Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}